Medpace Holdings, Inc. (MEDP) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $191.8M sold). 1 member of Congress reported 2 purchases vs 0 sales. Latest close $646.87 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 29, 2026 · Congress to Nov 16, 2026.
Giverny Capital · Vulcan Value Partners · Mairs & Power Funds — 5 tracked funds hold MEDP. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 25 sales ($191.8M). Insider trading 1 member of Congress reported buying (2 purchases vs 0 sales). Latest buy: May 15, 2026. Politician trading
BADGER METER INC (BMI) · AUTOMATIC DATA PROCESSING INC (ADP) · VEEVA SYSTEMS INC (VEEV) · LITTELFUSE INC /DE (LFUS) · TJX COMPANIES INC /DE/ (TJX) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Giverny Capital | 4.52% | 253,931 | TRIMMED (-0.8%) Q3 filed Nov 12 |
| Vulcan Value Partners | 2.28% | 141,743 | TRIMMED (-30.2%) Q3 filed Nov 10 |
| Mairs & Power Funds | 0.42% | 86,715 | ADDED (+1.2%) Q3 filed Nov 16 |
| Fundsmith | 0.20% | 52,372 | TRIMMED (-16.4%) Q3 filed Nov 16 |
| PineStone Asset Management | 0.01% | 1,760 | TRIMMED (-33.3%) Q3 filed Oct 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +20.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 690 of 8,857 filers |
| Long-only filers among them | 688 |
| Change vs 2026 Q1 | -25 net · 638 entered · 663 exited |
| Shares reported, all filers | 24,528,825 |
| Reported value, all filers | $11.4B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Services-Commercial Physical & Biological Research (SIC 8731) |
| Revenue · FY2025 | $2.5B |
| Net income · FY2025 | $451.1M |
| Total assets · FY2025 | $2.0B |
| Shares outstanding | 27,971,686 |
| Market cap (at latest close) | $18.1B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 16, 2026.
| Shares short · Oct 15, 2026 | 1,612,486 |
| Share of shares outstanding | 5.76% |
| Days to cover | 6.59 |
Shares short at recent settlements — Jul 31, 2026: 1.7M · Aug 14, 2026: 1.6M · Aug 31, 2026: 1.7M · Sep 15, 2026: 1.7M · Sep 30, 2026: 1.6M · Oct 15, 2026: 1.6M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 16, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 3 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 16, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 25 sales by 7 insiders ($191.8M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | Sell | 1,245 | $690.00 | $859.0K | SEC filing |
| Oct 27, 2026 | BURWIG SUSAN E | Exec. VP, Operations | Sell | 3,940 | $677.00 | $2.7M | SEC filing |
| Oct 26, 2026 | BURWIG SUSAN E | Exec. VP, Operations | Sell | 16,060 | $677.00 | $10.9M | SEC filing |
| Sep 30, 2026 | Troendle August J. | President & CEO | Sell | 21,966 | $625.47 | $13.7M | SEC filing |
| Sep 29, 2026 | Troendle August J. | President & CEO | Sell | 26,701 | $621.02 | $16.6M | SEC filing |
| Sep 28, 2026 | Troendle August J. | President & CEO | Sell | 2,410 | $620.07 | $1.5M | SEC filing |
| Sep 25, 2026 | Troendle August J. | President & CEO | Sell | 154 | $620.60 | $95.6K | SEC filing |
| Sep 24, 2026 | Troendle August J. | President & CEO | Sell | 27,833 | $621.33 | $17.3M | SEC filing |
| Sep 23, 2026 | Troendle August J. | President & CEO | Sell | 16,083 | $628.64 | $10.1M | SEC filing |
| Sep 22, 2026 | Troendle August J. | President & CEO | Sell | 49,018 | $628.11 | $30.8M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Kraft Robert O. | Director | 3,858 | $2.4M | Aug 26, 2026 | SEC filing |
| Aug 20, 2026 | Brady Kevin M. | Officer | 3,400 | $2.1M | Aug 20, 2026 | SEC filing |
| Aug 19, 2026 | Carley Brian T | Director | 5,000 | $3.0M | Aug 19, 2026 | SEC filing |
| Aug 19, 2026 | DAVENPORT FRED B JR | Director | 7,283 | $4.4M | Aug 19, 2026 | SEC filing |
| Aug 11, 2026 | McCarthy Cornelius P. III | Director | 1,140 | $690.1K | Aug 11, 2026 | SEC filing |
| Aug 7, 2026 | McCarthy Cornelius P. III | Director | 795 | $465.1K | Aug 7, 2026 | SEC filing |
| Jul 29, 2026 | GEIGER JESSE J | Former Officer | 11,000 | $7.0M | Jul 23, 2026 | SEC filing |
| Jul 28, 2026 | BURWIG SUSAN E | Officer | 7,500 | $4.5M | Jul 28, 2026 | SEC filing |
| Jul 28, 2026 | GEIGER JESSE J | Former Officer | 4,000 | $2.4M | Jul 28, 2026 | SEC filing |
| Jul 27, 2026 | August J. Troendle | Chairman | 307,959 | $184.8M | Jul 27, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Sep 28, 2026 | SCHEDULE 13D/A | +5.0% (close Sep 29, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Sep 29, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | August J. Troendle | SC 13D/A | 5,396,508 | 19.1% | Sep 24, 2026 | SEC filing |
| Aug 14, 2026 | T. Rowe Price Associates, Inc. | SC 13G | 2,069,679 | 7.2% | Jun 30, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Dec 1, 2025 | August J. Troendle | SC 13D/A | 5,682,934 | 20.0% | Nov 26, 2025 | SEC filing |
| Mar 11, 2025 | August J. Troendle | SC 13D/A | 6,018,308 | 19.5% | Mar 7, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (2 purchases vs 0 sales). Bought by Republicans. Latest buy: May 15, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Taylor, David J. | House | R | 2 | 0 | May 15, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Services-Commercial Physical & Biological Research (SIC 8731). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Growth — Revenue up every year for 5 straight years
· O'Neil CAN SLIM — Explosive earnings growth leaders
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Growth — Latest revenue: $2.5B · 5-yr revenue CAGR: 22.3% · Straight growth years: 9
· O'Neil CAN SLIM — 3-yr EPS growth: 28.0% · ROE: 98.3% · Latest revenue growth: 20.0%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.54 · Operating cash flow: $713.2M · Net income: $451.1M
· Shareholder Yield — Shareholder yield: 4.6% · of which dividends: 0.0% · of which buybacks: 4.6%
· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 0 · Latest buy: May 15, 2026
· Distress Risk (Altman Z″) — Z″-Score: 0.20 · Working capital / assets: -0.18 · Retained earnings / assets: -0.23 · EBIT / assets: 0.27 · Equity / liabilities: 0.30
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2022 Q3, ranked #35 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 3 | 0.0% | -13.0% | +2.9% | -15.9% |
| Share count tripled (3x) | 1 | 100.0% | +49.8% | +8.6% | +41.2% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold MEDP — ranked by lift, the co-holding pattern described in Methodology: BADGER METER INC (BMI) · AUTOMATIC DATA PROCESSING INC (ADP) · VEEVA SYSTEMS INC (VEEV) · LITTELFUSE INC /DE (LFUS) · TJX COMPANIES INC /DE/ (TJX) · ANALOG DEVICES INC (ADI).
| Filed | Items | Source |
|---|---|---|
| Oct 21, 2026 | 2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Jul 22, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jun 4, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
BADGER METER INC (BMI) · Track Record: how the signals scored · Practice timing on MEDP
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.